Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial

Abstract Objectives Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: J. P. Desilles, C. Gregoire, C. Le Cossec, J. Lambert, O. Mophawe, M. R. Losser, F. Lambiotte, S. Le Tacon, M. Cantier, N. Engrand, P. Trouiller, J. Pottecher
Format: Artigo
Idioma:Inglês
Publicat: BMC 2020-06-01
Col·lecció:Trials
Matèries:
COVID-19
Randomised controlled trial
Lung damage
Neutrophil extracellular traps
ARDS
Dornase alfa
Accés en línia:http://link.springer.com/article/10.1186/s13063-020-04488-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars